[Clinical observation on intranasal budesonide in chronic nonallergic rhinitis].
OBJECTIVE
An open randomized comparative study was conducted in order to observe the efficacy and safety about intranasal Budesonide in the treatment of chronic nonallergic rhinitis.


METHODS
Forty-two patients with chronic nonallergic rhinitis were treated with Budesonide aqueous nasal spray (256 microg once daily intranasally) for 8 weeks. All the patients were asked for return at week 1 and week 8. Efficacy was evaluated by measurement of nasal symptom scores and sign scores at week 0, week 1 and week 8.


RESULTS
All the parameters measured were improved after treatment. Specifically, from week 0 to week 1, the scores of nasal secretions, itchy feeling of the nose and headache showed a significant decrease than that before treatment. From week 0 to week 8, the scores of nasal obstruction, nasal secretions, itchy feeling of the nose, closed rhinolalia and headache were significantly less than the record at week 0. However, there were not significant influences on the smell disturbances, dryness of the throat. No serious adverse events were reported in the study.


CONCLUSIONS
Intranasal Budesonide is effective and safe in alleviating the symptoms of chronic nonallergic rhinitis.
Zhuang
Huiwen
H
Otorhinolaryngology Hospital of the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China. zhwgz@hotmail.com
Wen
Weiping
W
D000281:Administration, Intranasal; D000328:Adult; D000368:Aged; D019819:Budesonide / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009666:Nose / Q000503:physiopathology; D012220:Rhinitis / Q000188:drug therapy*; D016896:Treatment Outcome
D005938:Glucocorticoids; D019819:Budesonide